« Return to News | CROs/Service Providers

PPD Sells Biomarker Business to Caprion

Wednesday, January 27, 2010 07:59 AM

PPD’s plan to refocus its contract research organization (CRO) business is one step closer to final with the recent sale of its biomarker services division, PPD Biomarker Discovery Sciences, to Montreal-based Caprion Proteomics.

Caprion purchased the shares and assets of the Menlo Park, Calif., business Dec. 31, 2009, for an undisclosed sum. With the sale of this portion of its business, PPD next plans to spin off its compound partnering business, creating two independent public companies. Only the CRO business will maintain the PPD name.

Caprion provides proteomics biomarker services and said the PPD acquisition will help the company further its market leadership position. The company will fulfill PPD’s existing contractual obligations from both Menlo Park and Montreal. 

“We are very pleased to add the solid scientific capabilities, experience and customer relationships of PPD’s biomarker unit to Caprion’s rapidly growing biomarker services business,” said Martin LeBlanc, president and CEO of Caprion, in a statement. “By acquiring this business, we will expand our capacity and be able to better meet the growing biomarker needs of our current and future clients.”

Caprion expects the acquisition to be immediately accretive.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.